Skip to main navigation Skip to search Skip to main content

The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

  • Lindsay B. Kilburn*
  • , Dong Anh Khuong-Quang
  • , Jordan R. Hansford
  • , Daniel Landi
  • , Jasper van der Lugt
  • , Sarah E.S. Leary
  • , Pablo Hernáiz Driever
  • , Simon Bailey
  • , Sébastien Perreault
  • , Geoffrey McCowage
  • , Angela J. Waanders
  • , David S. Ziegler
  • , Olaf Witt
  • , Patricia A. Baxter
  • , Hyoung Jin Kang
  • , Timothy E. Hassall
  • , Jung Woo Han
  • , Darren Hargrave
  • , Andrea T. Franson
  • , Michal Yalon Oren
    • Helen Toledano, Valérie Larouche, Cassie Kline, Mohamed S. Abdelbaki, Nada Jabado, Nicholas G. Gottardo, Nicolas U. Gerber, Nicholas S. Whipple, Devorah Segal, Susan N. Chi, Liat Oren, Enrica E.K. Tan, Sabine Mueller, Izzy Cornelio, Lisa McLeod, Xin Zhao, Ashley Walter, Daniel Da Costa, Peter Manley, Samuel C. Blackman, Roger J. Packer, Karsten Nysom
*Corresponding author for this work
  • Children’s National Hospital
  • Royal Children's Hospital Melbourne
  • Women's and Children's Hospital Adelaide
  • Adelaide University
  • Duke University
  • Princess Máxima Center for Pediatric Oncology
  • Seattle Children’s
  • Charité – Universitätsmedizin Berlin
  • Newcastle University
  • University of Montreal
  • Sydney Children’s Hospitals Network
  • Children's Memorial Hospital
  • Sydney Children's Hospital
  • University of New South Wales
  • University of New South Wales
  • Hopp Children´s Cancer Center Heidelberg (KiTZ)
  • German Cancer Research Center
  • Heidelberg University 
  • Baylor College of Medicine
  • Seoul National University
  • Children’s Health Queensland
  • Yonsei University
  • University College London
  • University of Michigan, Ann Arbor
  • Sheba Medical Center at Tel Hashomer
  • Ctr. Hosp. Universitaire de Quebec
  • The Children's Hospital of Philadelphia
  • Washington University St. Louis
  • McGill University
  • Telethon Institute for Child Health Research
  • University of Zurich
  • University of Utah
  • New York University
  • Dana-Farber Cancer Institute
  • General Directorate Rambam Health Care Campus
  • KK Women's and Children's Hospital
  • University of California at San Francisco
  • Day One Biopharmaceuticals, Inc.
  • University of Copenhagen

Research output: Contribution to journal › Article › peer-review

164 Scopus citations

Fingerprint

Dive into the research topics of 'The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Keyphrases